OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (58)	8/3/1999 3:31:00 PM
From: scaram(o)uche	Read Replies (1) of 447

Release said that purchase didn't include anything anywhere near SIBI litigation. To further cover rear, here's a snippet from the KDUS 10-K...... The injunction does not bar the Company from providing certain specified screening assays that utilize a readout method covered by the SIBIA patent to Bristol-Myers Squibb and SmithKline Beecham, two of the Company's collaborative partners, and does not bar Bristol-Myers Squibb or SmithKline Beecham from using those assays for screening purposes, up to a specified number of compounds and/or natural product samples. The injunction does not affect Solvay Pharmaceuticals since it utilizes screening assays obtained from the Company solely outside the United States.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next